CD24 and cancer: We are currently developing less immunogenic, potentially clinically applicable delivery systems based on small natural vesicles, such as exosomes, as they can directly target cancer cells through highly specific small antibody fragments that are over-expressed in most human cancer cells and rarely expressed on normal cells as, e.g., CD24 [22].